ZOMDF Zomedica Corp.
Pharmaceutical Preparations · OTC · SEC CIK 1684144 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.3%
TTM net income YoY81.1%
TTM EPS YoY88.9%
Revenue 3-yr CAGR17.2%
Net income 3-yr CAGR—
Margins
Gross margin64.0%
Operating margin-45.4%
Net margin-41.4%
FCF margin-30.8%
EBITDA margin-40.0%
Returns
ROE-14.3%
ROA-13.0%
ROIC (approx.)-13.3%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets9.3%
Debt / equity0.00x
Current ratio6.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.90M | $9.51M | $8.80M | $10.47M | $8.10M | $6.96M | $6.50M | $7.89M |
| Cost of revenue | $3.85M | $3.47M | $3.31M | $3.30M | $2.66M | $2.30M | $2.09M | $2.35M |
| Gross profit | $6.04M | $6.04M | $5.48M | $7.17M | $5.44M | $4.67M | $4.41M | $5.55M |
| R&D expense | $1.20M | $1.07M | $1.15M | $1.64M | $1.78M | $1.89M | $1.85M | $2.15M |
| SG&A expense | $4.71M | $5.38M | $5.41M | $6.17M | $5.90M | $6.16M | $6.26M | $6.29M |
| Operating income | -$3.42M | -$4.08M | -$4.90M | -$5.16M | -$6.61M | -$8.04M | -$64.55M | -$8.16M |
| Pretax income | -$3.16M | -$3.74M | -$4.50M | -$4.74M | -$6.14M | -$7.39M | -$63.87M | -$7.42M |
| Income tax | $9,000 | $26,000 | $39,000 | -$214,000 | -$19,000 | $12,000 | -$57,000 | -$221,000 |
| Net income | -$3.17M | -$3.77M | -$4.53M | -$4.53M | -$6.12M | -$7.40M | -$63.81M | -$7.19M |
| EBITDA | -$2.89M | -$3.56M | -$4.38M | -$4.64M | -$6.10M | -$7.53M | -$64.03M | -$7.72M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | -0.01 | -0.01 | -0.07 | — |
| EPS (diluted) | — | — | 0.00 | — | -0.01 | -0.01 | -0.07 | — |
| Weighted avg. shares (diluted) | — | — | — | — | 979.95M | 979.95M | 979.95M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.28M | $7.19M | $9.37M | $9.02M | $7.50M | $8.13M | $8.84M | $7.02M |
| Receivables | $6.79M | $5.67M | $4.43M | $3.01M | $3.14M | $2.30M | $1.57M | $2.42M |
| Inventory | $5.77M | $6.05M | $5.88M | $5.54M | $5.52M | $5.67M | $5.36M | $5.06M |
| Current assets | $55.44M | $57.89M | $60.03M | $64.04M | $64.69M | $68.60M | $73.22M | $81.77M |
| PP&E, net | $19.56M | $20.04M | $20.46M | $20.91M | $21.38M | $21.86M | $22.24M | $24.59M |
| Goodwill | — | — | — | $0 | $0 | $0 | — | $45.56M |
| Intangibles | $36.65M | $37.37M | $37.98M | $38.81M | $40.10M | $41.40M | $42.77M | $52.54M |
| Total assets | $115.03M | $118.15M | $121.53M | $127.04M | $130.91M | $136.47M | $142.99M | $207.36M |
| Current liabilities | $9.10M | $9.00M | $8.56M | $9.45M | $8.43M | $8.13M | $7.41M | $9.33M |
| Total liabilities | $10.74M | $10.86M | $10.59M | $11.64M | $11.22M | $11.12M | $10.55M | $11.70M |
| Shareholders' equity | $104.28M | $107.28M | $110.94M | $115.40M | $119.69M | $125.36M | $132.44M | $195.66M |
| Shares outstanding | 979.95M | 979.95M | 979.95M | 979.95M | 979.95M | 979.95M | 979.95M | 979.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.77M | -$2.55M | -$5.26M | -$899,000 | -$4.66M | -$5.44M | -$6.65M | -$4.53M |
| Capital expenditure | $187,000 | $92,000 | $60,000 | $107,000 | $43,000 | $137,000 | $280,000 | $575,000 |
| Free cash flow | -$2.96M | -$2.64M | -$5.32M | -$1.01M | -$4.70M | -$5.58M | -$6.93M | -$5.10M |
| Investing cash flow | $2.84M | $386,000 | $5.62M | $2.45M | $4.04M | $4.68M | $8.41M | $1.92M |
| Financing cash flow | — | — | — | — | — | — | — | $0 |
| Depreciation & amortization | $535,000 | $526,000 | $519,000 | $519,000 | $506,000 | $509,000 | $521,000 | $443,000 |
| Stock-based compensation | -$38,000 | $69,000 | $643,000 | $727,000 | $867,000 | $260,000 | $618,000 | $345,000 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.